Vanda Pharmaceuticals Inc. VNDA, +4.26% shares fell in the extended session Wednesday after the biotech drug developer said a study of its treatment for a type of eczema did not reach the stated goal. Vanda shares fell 6.7% to $15.86 after hours, following a brief halt in trading. The company said a mid-stage clinical study of its drug tradipitant showed that while the drug showed improvement in itching in patients with atopic dermatitis compared with a placebo, the results were not statistically significant.
Tenet Healthcare, facing shareholder-activist pressure, is exploring strategic options including a possible sale of the big hospital company.
42% of the reviews came from unverified purchasers who didn’t buy the book from Amazon.
Los Angeles officially won the rights to organize the 2028 Summer Olympics on Wednesday, completing an unprecedented arrangement the International Olympic Committee struck earlier this summer to name the next two summer Games sites at once.